Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide +/- Rituximab Consolidation and Maintenance in CLL/SLL Post-Transplant
NCT00833534Phase 2Withdrawn
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of lenalidomide in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Efficacy of lenalidomide with or without rituximab and Disease-free survival at 2 years. Planned start Feb 2009; status: withdrawn.
02
Drugs
lenalidomide
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT00833534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00833534.